Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2440979 | 1.00 | MAOB (0.46) | MAOBENPP2PTGS2PTGS1AKR1C3 | |
| SCHEMBL2440978 | 1.00 | MAOB (0.46) | MAOBENPP2PTGS2PTGS1AKR1C3 | |
| SCHEMBL9720723 | 0.87 | MAOB (0.55) | MAOBENPP2PTGS2PTGS1AKR1C3 | |
| SCHEMBL9720721 | 0.87 | MAOB (0.55) | MAOBENPP2PTGS2PTGS1AKR1C3 | |
| SCHEMBL20194 | 0.80 | ENPP2 (0.50) | ENPP2PTGS2 | |
| SCHEMBL27722400 | 0.79 | PTGS2 (0.59) | PTGS2AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL9720714 | 0.79 | MAOB (0.49) | MAOBENPP2PTGS2PTGS1AKR1C3 | |
| SCHEMBL17439304 | 0.78 | PTGS2 (0.64) | PTGS2PTGS1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL5698418 | 0.78 | PTGS2 (0.64) | PTGS2PTGS1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL16052791 | 0.78 | PTGS2 (0.64) | PTGS2PTGS1AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318748-B2 | Cathepsin cysteine protease inhibitors | Merck, Sharp & Dohme Corp. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110230446-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| EP-1482924-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230446-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | MAOB 1173/4885ENPP2 304/4885PTGS2 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.